Capricor Therapeutics, Inc.
CAPR Healthcare Biotechnology
Capricor Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $22.3 million, down 11.5% from fiscal 2023. In the quarter to June 2026, revenue fell 7.92%, EPS fell 22.8% and free cash flow fell 72.9%, each against the same quarter a year earlier.
Follow CAPR
Capricor Therapeutics, Inc. (CAPR) Altman Z-score
Capricor Therapeutics, Inc.'s Altman Z-score for fiscal 2024 is 10.32, in the safe zone (above 2.99).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2024 | 10.32 | 12.47 |
| FY2023 | −2.15 | 1.64 |
| FY2022 | −3.79 | (3.48) |
| FY2021 | −0.31 | (1.51) |
| FY2020 | 1.20 | 11.07 |
| FY2019 | −9.87 | 3.03 |
| FY2018 | −12.89 | (11.41) |
| FY2017 | −1.49 | 3.17 |
| FY2016 | −4.66 | (1.62) |
| FY2015 | −3.04 | — |
How fiscal 2024’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.84 | — | 1.00 | |
| Retained earnings / total assets | (1.17) | — | −1.64 | |
| EBIT / total assets | (0.25) | — | −0.82 | |
| Market value of equity / total liabilities | 19.43 | — | 11.66 | |
| Sales / total assets | 0.13 | — | 0.13 | |
| Altman Z-score | Safe zone | 10.32 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Safe zone | 6.08 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| CAPR Capricor Therapeutics, Inc. | 10.3× |
| DMAC DiaMedica Therapeutics, Inc. compare | 6.7× |
| ENTX Entera Bio Ltd. compare | 6.2× |
| ASMB Assembly Biosciences, Inc. compare | 1.1× |
| PRTA Prothena Corporation plc compare | −0.2× |
| EDIT Editas Medicine, Inc. compare | −13.4× |
| TECX Tectonic Therapeutic, Inc. compare | — |
| YDES YD Bio Limited compare | — |
| RZLT Rezolute, Inc. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets